Claims for Patent: 9,814,714

Summary for Patent: 9,814,714

Title:	Kinase modulation, and indications therefor
Abstract:	The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.
Inventor(s):	Ibrahim; Prabha N. (Mountain View, CA), Zhang; Chao (Moraga, CA), Spevak; Wayne (Berkeley, CA), Zhang; Jiazhong (Foster City, CA), Wu; Guoxian (Palo Alto, CA), Lin; Jack (Hercules, CA), Cho; Hanna (Oakland, CA), Nespi; Marika (Berkeley, CA), Shi; Songyuan (Fremont, CA), Ewing; Todd (Walnut Creek, CA), Zhang; Ying (Fremont, CA), Bollag; Gideon (Orinda, CA)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	15/160,729
Patent Claims:	1. A method of treating or inhibiting a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF, in a subject suffering from or at risk for a said disease or condition, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula I: ##STR00003## or a pharmaceutically acceptable salt, isomer, tautomer or deuterated form thereof. 2. The method according to claim 1, wherein the non-activation of the MAPK pathway or non-inducement of expression of MAPK pathway genes in cells harboring wild-type BRAF comprises inhibition of phosphor-ERK (pERK) in BRAF wild-type cells. 3. The method according to claim 1, wherein the non-activation of the MAPK pathway or non-inducement of expression of the MAPK pathway comprises inhibition of pERK and pMEK in BRAF wild-type cells. 4. The method according to claim 1, wherein the non-activation of the MAPK pathway or non-inducement of expression of MAPK pathway genes in cells harboring wild-type BRAF inhibits stimulation of cell growth. 5. The method according to claim 1, wherein the non-activation of the MAPK pathway or non-inducement of expression of MAPK pathway genes in cells harboring wild-type BRAF inhibits stimulation of skin neoplasms. 6. The method according to claim 1, wherein the therapeutically effective amount of Formula I is administered in a pharmaceutical composition further comprising a pharmaceutically acceptable excipient or carrier. 7. The method according to claim 1, wherein the therapeutically effective amount of Formula I is administered in a pharmaceutical composition further comprising another therapeutic agent. 8. The method according to claim 1, wherein the BRAF V600 mutation or BRAF fusion mutation related disease or condition is melanoma, colorectal cancer, papillary thyroid cancer, anaplastic thyroid cancer, ovarian cancer, non-small-cell lung cancer, gastric cancer, cholangiocarcinoma, Barrett's esophageal cancer, head and neck cancer, hepatocellular carcinoma, Langerhan's cell histiocytosis, gastrointestinal stromal cell tumours, multiple myeloma, pediatric astrocytomas, pleomorphic xanthoastrocytomas, chronic myeloid leukemia, acute myelomonocytic leukemia, biphenotypic B myelomonocytic leukemia, acute myeloid leukemia, hairy cell leukemia, nevi, Erdheim-Chester disease, malignant peripheral nerve sheath tumor, inflammatory and autoimmune disease, tenosynovial giant cell tumor, pigmented villonodular synovitis, giant cell tumor of tendon sheath, giant cell tumor of bone, cervical cancer, endometrial cancer, germ cell tumors, prostate cancer, bladder cancer, myopericytoma, metanephric adenoma, pancreatic neoplasms, neuroendocrine tumors, endocrine tumors, adrenal tumors, adrenal medullary tumors, cystadenocarcinoma of the parotid, glioblastoma multiforme, bile duct cancer including bile duct adenoma, B-cell chronic lymphoproliferative disorder, dendritic cell sarcomas, histiocytic sarcomas, or lymphoma. 9. The method according to claim 1, wherein the BRAF V600 mutation or BRAF fusion mutation related disease or condition is hepatocellular carcinoma, Langerhan's cell histiocytosis, gastrointestinal stromal cell tumours, multiple myeloma, pediatric astrocytomas, pleomorphic xanthoastrocytomas, chronic myeloid leukemia, acute myelomonocytic leukemia, biphenotypic B myelomonocytic leukemia, acute myeloid leukemia, hairy cell leukemia, or nevi. 10. The method according to claim 1, wherein the BRAF V600 mutation or BRAF fusion mutation related disease or condition is melanoma, colorectal cancer, papillary thyroid cancer, anaplastic thyroid cancer, ovarian cancer, non-small-cell lung cancer, gastric cancer, cholangiocarcinoma, Barrett's esophageal cancer, or head and neck cancer. 11. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is Erdheim-Chester disease. 12. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is melanoma. 13. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is metastatic melanoma. 14. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is colorectal cancer. 15. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is papillary thyroid cancer. 16. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is anaplastic thyroid cancer. 17. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is ovarian cancer. 18. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is non-small-cell lung cancer. 19. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is gastric cancer. 20. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is Langerhan's cell histiocytosis. 21. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is acute myeloid leukemia. 22. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is multiple myeloma. 23. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is malignant peripheral nerve sheath tumor. 24. The method according to claim 1, wherein the BRAF fusion mutation related disease or condition is pediatric astrocytomas. 25. The method according to claim 1, wherein the BRAF V600 mutation is one or more mutations selected from the group consisting of V600E, V600K, V600D, V600A, V600G, V600M, and V600R. 26. The method according to claim 1, wherein the BRAF V600 mutation comprises a V600E mutation and a V600K mutation. 27. The method according to claim 1, wherein the BRAF V600 mutation comprises a V600E mutation. 28. The method according to claim 1, further comprising administering to said subject one or more of the following agents: adozelesin, altretamine, bendamustine, bizelesin, busulfan, carboplatin, carboquone, carmofur, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, etoglucid, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mannosulfan, mechlorethamine, melphalan, mitobronitol, nedaplatin, nimustine, oxaliplatin, piposulfan, prednimustine, procarbazine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, thiotepa, treosulfan, triaziquone, triethylenemelamine, triplatin tetranitrate, trofosphamide, uramustine, aclarubicin, amrubicin, bleomycin, dactinomycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, idarubicin, menogaril, mitomycin, neocarzinostatin, pentostatin, pirarubicin, plicamycin, valrubicin, zorubicin, aminopterin, azacitidine, azathioprine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabinc, 5-fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, azathioprine, raltitrexed, tegafur-uracil, thioguanine, trimethoprim, trimetrexate, vidarabine, alemtuzumab, pembrolizumab, nivolumab, bevacizumab, cetuximab, galiximab, gemtuzumab, panitumumab, pertuzumab, rituximab, tositumomab, trastuzumab, 90Y-ibritumomab tiuxetan, ipilimumab, tremelinuimab, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, toremifene, DJ-927, docetaxel, TPI 287, larotaxel, ortataxel, paclitaxel, DHA-paclitaxel, tesetaxel, alitretinoin, bexarotene, fenretinide, isotretinoin, tretinoin, demecolcine, homoharringtonine, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, an antiangiogenic agent, including, but not limited to, Neovastat, ABT-510, 2-methoxyestradiol, lenalidomide, thalidomide, amsacrine, edotecarin, etoposide, etoposide phosphate, exatecan, irinotecan, lucanthone, mitoxantrone, pixantrone, rubitecan, teniposide, topotecan, 9-aminocamptothecin, axitinib, erlotinib, gefitinib, flavopiridol, imatinib mesylate, cabozantinib, lapalinib, motesanib diphosphate, nilotinib, seliciclib, sorafenib, sunitinib malate, AEE-788, BMS-599626, 7-hydroxystaurosporine, vatalanib, bortezomib, geldanamycin, rapamycin, imiquimod, interferon-a, interleukin-2, 3-amino-2-carboxyaldehyde thiosemicarbazone, altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elescloniol, eribulin mesylate, ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactonc, tiazofurin, temsirolimus, everolimus, deforolimus, a PI3K inhibitor, a Cdk4 inhibitor, a Akt inhibitor, a Hsp90 inhibitor, an EGFR inhibitor, an IDO inhibitor, a farnesyltransferase inhibitor, a MEK inhibitor, a BET inhibitor, AS703026, selumetinib, AZD8330, BIX02188, PD184352, D-87503, GS 1 120212, PD0325901, PD3 18088, PD98059, PDEAl 19, or TAK-733. 29. The method according to claim 7, wherein the another therapeutic agent is adozelesin, altretamine, bendamustine, bizelesin, busulfan, carboplatin, carboquone, carmofur, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, etoglucid, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mannosulfan, mechlorethamine, melphalan, mitobronitol, nedaplatin, nimustine, oxaliplatin, piposulfan, prednimustine, procarbazine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, thiotepa, treosulfan, triaziquone, triethylenemelamine, triplatin tetranitrate, trofosphamide, uramustine, aclarubicin, amrubicin, bleomycin, dactinomycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, idarubicin, menogaril, mitomycin, neocarzinostatin, pentostatin, pirarubicin, plicamycin, valrubicin, zorubicin, aminopterin, azacitidine, azathioprine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabinc, 5-fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, azathioprine, raltitrexed, tegafur-uracil, thioguanine, trimethoprim, trimetrexate, vidarabine, alemtuzumab, pembrolizumab, nivolumab, bevacizumab, cetuximab, galiximab, gemtuzumab, panitumumab, pertuzumab, rituximab, tositumomab, trastuzumab, 90Y-ibritumomab tiuxetan, ipilimumab, tremelinuimab, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, toremifene, DJ-927, docetaxel, TPI 287, larotaxel, ortataxel, paclitaxel, DHA-paclitaxel, tesetaxel, alitretinoin, bexarotene, fenretinide, isotretinoin, tretinoin, demecolcine, homoharringtonine, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, an antiangiogenic agent, including, but not limited to, Neovastat, ABT-510, 2-methoxyestradiol, lenalidomide, thalidomide, amsacrine, edotecarin, etoposide, etoposide phosphate, exatecan, irinotecan, lucanthone, mitoxantrone, pixantrone, rubitecan, teniposide, topotecan, 9-aminocamptothecin, axitinib, erlotinib, gefitinib, flavopiridol, imatinib mesylate, cabozantinib, lapalinib, motesanib diphosphate, nilotinib, seliciclib, sorafenib, sunitinib malate, AEE-788, BMS-599626, 7-hydroxystaurosporine, vatalanib, bortezomib, geldanamycin, rapamycin, imiquimod, interferon-a, interleukin-2, 3-amino-2-carboxyaldehyde thiosemicarbazone, altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elescloniol, eribulin mesylate, ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactonc, tiazofurin, temsirolimus, everolimus, deforolimus, a PI3K inhibitor, a Cdk4 inhibitor, a Akt inhibitor, a Hsp90 inhibitor, an EGFR inhibitor, an IDO inhibitor, a farnesyltransferase inhibitor, a MEK inhibitor, a BET inhibitor, AS703026, selumetinib, AZD8330, BIX02188, PD184352, D-87503, GS 1 120212, PD0325901, PD3 18088, PD98059, PDEAl 19, or TAK-733. 30. The method according to claim 1, wherein the BRAF V600 mutation related disease or condition is cholangiocarcinoma. 31. method according to claim 1, wherein the BRAF V600 mutation related disease or condition is glioblastoma multiforme.

Details for Patent 9,814,714

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2035-05-22
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2035-05-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2035-05-22